Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
23,276,571
-
Share change
-
-5,280,233
-
Total reported value
-
$46,558,000
-
Put/Call ratio
-
110%
-
Price per share
-
$2.00
-
Number of holders
-
43
-
Value change
-
-$13,958,785
-
Number of buys
-
26
-
Number of sells
-
11
Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS as of Q3 2019
As of 30 Sep 2019,
NABRIVA THERAPEUTICS PLC - SHS was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,276,571 shares.
The largest 10 holders included
FMR LLC, ORBIMED ADVISORS LLC, FRAZIER MANAGEMENT LLC, Rock Springs Capital Management LP, Aisling Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, DIMENSIONAL FUND ADVISORS LP, JPMORGAN CHASE & CO, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and MORGAN STANLEY.
This page lists
43
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.